Member Info for Wisheyedbortum

What a fantastic time to be in both IQE and ITM! Long may it continue. GLA.

Only bought into these last month....just in time! ITM and IQE, Brilliant.

The MMs will only raise the sp if there is likely to be demand for the shares, which at present there isn't. Because of the secrecy behind the various deals going on regarding how much money is changing hands, the only time the sp will go up is when the figures are published. I have been following and investing in Avacta since 2009 and certainly, things have never looked more promising. However, there are better companies to invest in at the moment if you want to make money, which after all is the name of the game. Having said that, I still hold Avacta shares, although not as many as I used to. I am sure this will rocket in the not too distant future and continue to do so for some time to come.

Nice to see Avacta climbing for a change. A few more announcements like the last one and the £2.00 looks a distinct possibility.

Of course, the slight drawback is the undisclosed finances involved. We don't know if they are game changing amounts or not, but the fact that it's one of the big three is very encouraging and more of the same can only be a good thing. My guess would be Novartis.

....this morning, the first of many we hope.

And that's answered my second question!

was CCO of Promexus and not Avacta. Promexus employed Avacta's Affimer technology.

So that answers the question of why WAN is de-ramping Avacta like there's no tomorrow, but the next question is why has immersion set him/herself up purely to transfer WAN's de-ramping onto LSE?

It's the usual story with Avacta, wonderful trading update, but no financials. Where is the money? The MMS left the buy price where it is, so no one is buying and they've dropped the sell price, which means that people are selling. WAN made some very valid points, but finncap has put a target price of £2.00 within a year, so for now I am giving Avacta the benefit of the doubt and holding.

Well immersion, you perfectly entitled to Wans opinion.

Avacta salaries are decided by a non executive director remuneration committee so they do not reward themselves. £228k before tax for a person of Dr. Smith's calibre? It's not a lot.

Thanks SoleBoy, much appreciated. I think that the recent RNS demonstrates the board's confidence in the future of the company.

Sounds like you are doubting that this meeting actually took place and no, I am not a major shareholder. So we continued our discussions over a pub lunch at the Red Lion which is a short walk from Avacta and Dr. Smith asked me why I thought the SP was so low and what I thought could be done about it. I replied that I thought the MMs were getting people to sell because they had a large order to fill and possibly that they were aware of the potential of Avacta and were stocking up with shares in readiness for a sudden demand for the shares because of what might be announced in the January update. I said that I felt that the RNSs needed some indications of the value of the various partnerships and what potential income could be expected from them. Of course, as I mentioned before, the serious income will come from the big pharmas, but these negotiations are very secretive affairs. As for your last statement, Dr. Smith is a brilliant scientist and a very shrewd cookie, but he also has his feet firmly on the ground and cares about his investors big and small, plus, if you don't ask, you don't get.

This is the second time that my wife and I have visited Avacta, the first being at Wetherby during the days of AX1 and Optim. Apart from being a brilliant scientist, Dr. Smith is also a really nice guy and he went to great lengths to explain what the Affimers are capable of, where they could be used and how they are produced. Dr. Amrik Basran took us on a guided tour of the facility, which is full of brand new equipment, and explained the rudiments of affimer production. The main reason for our visit was to try to ascertain what all this means in terms of income and the share price and whether FinnCap's prediction of the SP at least doubling over the next 12 months was feasable, and the only way to do this was to talk to the CEO. With the information that I was given I came to the conclusion that Avacta has the potential to earn staggering amounts of money, but it just takes time to get the product out there to the big pharmas, get the licenses agreed and get the royalties rolling in.

Yesterday I had a most enjoyable and informative meeting with Dr. Alastair Smith. He is as mystified as the rest of us as to the ridiculously low share price which in no way represents the potential of Avacta. I had a quick tour of the new Cambridge facility which is impressive to say the least, but my main aim was to find out if the FinnCap prediction of "at least doubling of the SP over the next year" was indeed feasible. According to Dr. Smith, it certainly is. The major problem for the SP is that the partnerships that have been announced over the past few years are with companies that are relatively small and don't mind their names being made public. However, this group of partners is only the tip of the iceberg. Going on in the background are negotiations with large pharmas who wish for anonymity. Large amounts of cash will be flowing Avacta's way just for the initial trials with Affimers and then even larger amounts will be rolling in from licensing agreements once trials have been successful. Of course, not all trials will result in license agreements, but one thing is for sure, Affimers work. The uses for them are almost limitless and Avacta has the potential to make millions of pounds and us shareholders pretty rich. So I'm using the low SP as a buying opportunity and when investors and the MMs wake up to the massive potential and the almost certain success of this company I don't think that the SP will be where it is for much longer. Having said that, there are never any absolute certainties in investing, but Avacta is as near as you will get to one. There will be an update in January from Avacta. I have no idea what it will contain, but I'm certainly looking forward to it.

I think that the major problem for Avacta now is choosing which partners to grant licences to. There is no point in appointing partners that are not going to take Affimers to commercialization. I hope to find out more soon.

I expect that there are a number of contributors to this board that have been with Avacta longer than I have and will remember Midas and Optim and the hopes we had for those products, but this is the first time, to my knowledge, that any broker has put a seriously encouraging prediction, with a timescale, in writing. So I now believe that the time is right to reconsider what my investments are up to and re-assess the position that I hold with Avacta and to gather the available information to bring myself up to speed with what's happening, as I am ashamed to say that my interest has waned over the past couple of years.

http://www.proactiveinvestors.co.uk/companies/news/168332/city-broker-expecting-big-things-from-avacta-168332.html

http://www.proactiveinvestors.co.uk/companies/news/168332/city-broker-expecting-big-things-from-avacta-168332.html